Table 3.
Retail percent mark-ups on one adult equivalent treatment dose (%)
| Anti-malarial categories formulation | Retailer categories | ||||||
|---|---|---|---|---|---|---|---|
| All N = 382 | Pharmacies/ Clinical pharmacies N = 77 | Drug stores N = 75 | Mobile providers N = 101 | Grocery stores N = 57 | Village shops N = 72 | ||
| ACT | (n) | (418) | (119) | (85) | (103) | (51) | (59) |
| all were tablets | Median | 42.8 | 40.0 | 50.0 | 50.0 | 40.0 | 28.6 |
| IQR | 20.0–75.0 | 20.0–80.0 | 25.0–106.9 | 25.0–66.7 | 20.0–60.0 | 14.3–55.6 | |
| AMT | (n) | (177) | (32) | (37) | (46) | (29) | (33) |
| All | Median | 37.1 | 16.7 | 29.2 | 42.9 | 33.3 | 60.0 |
| IQR | 20.0–66.7 | 7.1–42.9 | 16.7–55.5 | 25.0–71.4 | 20.0–41.2 | 42.9–84.6 | |
| AMT | (n) | (121) | (13) | (28) | (26) | (25) | (29) |
| Tablet | Median | 37.1 | 15.4 | 37.1 | 33.3 | 33.3 | 60.0 |
| IQR | 20.0–71.4 | 7.7–25.9 | 16.7–90.5 | 25.0–66.7 | 20.0–41.2 | 37.1–87.5 | |
| AMT | (n) | (56) | (19) | (9) | (20) | (4) | (4) |
| Injectable | Median | 40.0 | 28.0 | 29.0 | 50.0 | 38.5 | 47.1 |
| IQR | 19.0–55.6 | 7.1–42.9 | 16.7–41.2 | 25.0–77.8 | 20.0–42.9 | 42.9–66.7 | |
| nAMT | (n) | (84) | (18) | (16) | (22) | (13) | (15) |
| All | Median | 100.0 | 53.8 | 100.0 | 127.3 | 177.8 | 100.0 |
| IQR | 50.0–185.7 | 7.1–100.0 | 66.7–150.0 | 50.0–185.7 | 33.3–185.7 | 66.7–150.0 | |
| nAMT | (n) | (64) | (18) | (13) | (10) | (10) | (13) |
| Tablet | Median | 100.0 | 53.8 | 100.0 | 100.0 | 185.7 | 366.7 |
| IQR | 50–185.7 | 7.1–100.0 | 66.7–115.5 | 80–233.3 | 33.3–185.7 | 66.7–366.7 | |
| nAMT | (n) | (20) | - | (3) | (12) | (3) | (2) |
| Injectable | Median | 166.7 | - | 191.7 | 150.0 | 33.3 | 366.7 |
| IQR | 50.0–200.0 | - | 191.7–275.0 | 50.0–185.7 | 17.6–177.8 | 66.7–366.7 | |
ACT is artemisinin combination therapy; AMT is artemisinin monotherapy; nAMT is non-artemisinin monotherapy; (n) is number of product observations; N is number of retailers for whom information was available; IQR is inter-quartile range. “-“drug category not stocked